| | | 续输注不可超过 24h。 | | | --- | --- | --- | --- | | | | 适用于 1 岁以上儿童哮喘的预防和长期治 | | | | | 疗，包括预防白天和夜间的哮喘症状，治疗 | | | | 孟鲁司特钠 | 对阿司匹林敏感的哮喘患者以及预防运动 | | | 8 | 颗粒 | 诱发的支气管收缩和减轻过敏性鼻炎引起 | 0.5g:4mg | | | | 的症状（ 2 岁至 5 岁儿童的季节性过敏性 | | | | | 鼻炎和常年性过敏性鼻炎）。 | | | | | 可用于治疗成年人（≥18 岁）由金黄色葡萄 球菌、铜绿假单胞菌、粘质沙雷氏菌、大肠 | | | | | 埃希菌、肺炎克雷伯杆菌、流感嗜血杆菌、 | | | | | 肺炎链球菌等细菌的敏感菌株所引起的下 | | | | | 列轻、中、重度感染，包括：医院获得性肺 | | | 9 | 左氧氟沙星 | 炎、社区获得性肺炎、急性细菌性鼻窦炎、 | 0.5g | | | 片 | 慢性支气管炎的急性细菌性发作、复杂性皮 | | | | | 肤及皮肤结构感染、非复杂性皮肤及皮肤软 | | | | | 组织感染、慢性细菌性前列腺炎、 ...

公司本次拟中选的15个药品品种2024年度合计销售额为2.28亿元，占公司2024年度营业收入比例为 15.75%；2025年前三季度合计销售额为1.57亿元(未经审计)，占公司2025年前三季度营业收入比例为 19.25%。若后续签订采购合同并实施，将进一步扩大产品的销量，提高市场占有率，提升公司品牌形 象，对公司未来的经营发展具有积极的影响。 格隆汇2月11日丨一品红(300723.SZ)公布，公司全资子公司广州一品红制药有限公司于近日参加了国家 组织集采药品协议期满品种接续采购办公室组织的国家组织集采药品协议期满品种接续采购的投标工 作。根据接续采购办公室于2026年2月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结 果公示》，公司共计15个药品品种拟中选本次接续采购。 ...

一品红公告，全资子公司广州一品红制药有限公司于近日参加了国家组织集采药品协议期满品种接续采 购办公室组织的国家组织集采药品协议期满品种接续采购的投标工作。根据接续采购办公室于2026年2 月10日发布的《国家组织集采药品协议期满品种接续采购拟中选结果公示》，公司共计15个药品品种拟 中选本次接续采购。 ...

Core Viewpoint - The company Yipinhong (300723) has stated that it will determine its profit distribution policy and plan in accordance with relevant laws and regulations, including the Company Law, Enterprise Accounting Standards, and the Guidelines for Listed Companies on Cash Dividends [1] Group 1 - The company will adhere to the Company Law and relevant accounting standards when establishing its profit distribution policy [1] - The profit distribution plan will also comply with the Guidelines for Listed Companies on Cash Dividends [1] - The company will follow its Articles of Association in determining the profit distribution [1]

经济观察网一品红（300723）近期完成对美国Arthrosi股权的出售交割，并持续推进股份回购计划。 近期事件 股份回购计划持续实施：截至2026年1月31日，公司通过集中竞价交易方式累计回购股份277.34万股， 占总股本的0.61%，使用资金总额约9,692.67万元。回购最高成交价为37.85元/股，最低为32.15元/股， 符合既定方案。 关联交易进展 2026年度日常关联交易安排：根据公告，公司临时股东会已于2026年1月14日审议通过2026年度日常关 联交易预计事项，总额不超过10,435万元，涉及与润尔眼科、云润生物等关联方的原材料购销、租赁等 交易。该事项已获批准，将在年度内执行。 以上内容基于公开资料整理，不构成投资建议。 根据近期公告和市场信息，一品红有以下值得关注的事件动态： 关联交易情况 出售参股公司美国Arthrosi股权交易完成交割：公司公告显示，Arthrosi与Sobi美国达成的并购协议已正 式生效，子公司瑞騰生物(香港)有限公司收到首期并购款约1.19亿美元(折合人民币约8.24亿元)。公司表 示将就后续进展及时履行信息披露义务。 公司状况 ...

Group 1 - Baichuan Co., Ltd. announced a recent price increase for some of its main products due to market supply and demand factors, but the sustainability of this price fluctuation remains uncertain, making it difficult to predict the impact on the company's performance [1] - Jincheng Co., Ltd. plans to increase its acquisition of CMH Company by an additional 42.50% stake, which will give it a total ownership of 97.5% and ultimate control over CMH [2] - Xinhang New Materials intends to raise no more than 1 billion yuan through a private placement of A-shares, with the funds allocated for projects including high-performance resin production and a composite materials innovation center [3] Group 2 - SMIC reported a sales revenue of $2.489 billion for Q4 2025, a 4.5% increase quarter-on-quarter, with an annual revenue of $9.327 billion, reflecting a 16.2% year-on-year growth [4] - China Railway Construction recently won 10 major projects, each valued over 1.5 billion yuan, totaling 45.142 billion yuan, which represents 4.23% of the company's audited revenue for 2024 [5] - Shenzhen Airport recorded a passenger throughput of 5.8795 million in January 2026, a year-on-year increase of 2.84% [6] Group 3 - China State Construction reported a new contract total of 399.5 billion yuan in January 2026, marking a 1.8% year-on-year increase [7] - Jindi Group's sales amount in January 2026 decreased by 45.78% year-on-year, with a signed area of 78,000 square meters [8] - Changyuan Power achieved a power generation of 3.971 billion kWh in January 2026, a year-on-year increase of 37.81% [9] Group 4 - Senyuan Electric is expected to win a project from the Southern Power Grid valued at 272 million yuan [10] - Chengyi Pharmaceutical's products are set to be selected for the national centralized procurement of expiring varieties [12] - Xinwufeng reported a 10.71% year-on-year decrease in pig sales volume in January 2026 [13] Group 5 - Shengnong Development's sales revenue in January 2026 increased by 40.48% year-on-year, with chicken sales volume rising by 42.79% [14] - Minglida announced the termination of its investment in a key component manufacturing project due to global economic uncertainties [15] - CITIC Securities reported that its subsidiary, Huaxia Fund, achieved a net profit of 2.396 billion yuan in 2025 [16] Group 6 - Pianzaihuang completed the first subject enrollment for its Phase II clinical trial of PZH2107 [17] - Xinzhou Bang reported a 16.56% year-on-year increase in net profit for 2025 [18] - Ankai Bus produced 761 vehicles in January 2026, a year-on-year increase of 35.65% [19] Group 7 - Weilan Bio plans to acquire a 50% stake in Aidimeng Weilan for 47 million yuan [20] - Ningbo Gaofa intends to establish a wholly-owned subsidiary with an investment of no more than 100 million yuan [21] - Shanghai Airport signed a leasing contract worth approximately 585 million yuan with the Shanghai Airport Group [22] Group 8 - Fosun Pharma's subsidiary received acceptance for a drug registration application [23] - Jindai Home's subsidiary invested in acquiring shares in a North American market company [24] - Huatong Co. reported a 1.45% year-on-year decrease in pig sales revenue in January 2026 [25] Group 9 - Yunnan Energy Investment's Nanchong Wind Power Project has been approved with a total installed capacity of 62,500 kW [28] - Youyan Silicon reported a 10.14% year-on-year decrease in net profit for 2025 [29] - Jinpu Titanium announced a temporary shutdown of its Nanjing Titanium White production due to reduced demand [30] Group 10 - Yipin Hong completed the sale of its stake in Arthrosi for a total of $9.5 billion in upfront payments [31] - Liande Co. stated that its gas turbine business currently has limited supply, with minimal impact on overall performance [32] - Tiens Wind Power signed new contracts worth 870 million yuan in the offshore engineering sector [33] Group 11 - Daqin Railway reported a freight volume of 31.28 million tons in January 2026, a year-on-year increase of 5% [34] - ST Mingcheng successfully dismissed all claims from Beijing Fusheng in a recent court ruling [35] - Zhiyang Innovation is planning to acquire control of Lingming Photon and will continue its stock suspension for up to five trading days [36][37] Group 12 - Fulai New Materials accelerated the commercialization of flexible sensors, preparing for mass production of its third-generation electronic skin products [38] - Minhe Co. reported a 36.89% year-on-year decrease in sales of broiler chicks in January 2026 [39] - Ruiang Gene received government subsidies totaling 2 million yuan [40] Group 13 - Huiyu Pharmaceutical's shareholder was forced to reduce holdings by 0.307% due to a court order [41] - Fuyuan Pharmaceutical's subsidiary obtained a drug registration certificate for a new oral solution [42] - Xuantai Pharmaceutical's product is set to be selected for national procurement [43] Group 14 - Chunqiu Electronics completed the cancellation of 9.1369 million repurchased shares [44] - Jinguang Electric won a bid worth approximately 28.8691 million yuan [45] - Hongda Co. plans to invest approximately 71.43 million yuan in a 110kV power transmission project [46] Group 15 - Nanchao Foods reported a 1.99% year-on-year decrease in revenue for January 2026 [47] - Shisheng Intelligent plans to repurchase shares worth between 17.5 million and 35 million yuan [48]

证券代码：300723 证券简称：一品红 公告编号：2026-008 一品红药业集团股份有限公司 关于出售参股公司美国 Arthrosi 公司股权的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 12 月，一品红药业集团股份有限公司（以下简称："公司"）的参 股公司美国 Arthrosi Therapeutics,Inc.（以下简称："Arthrosi"）与瑞典 Swedish Orphan Biovitrum AB（pub1）下属全资子公司 Sobi US Holding Corp.（以 下简称：Sobi 美国）签署并购协议，Sobi 美国拟以 9.5 亿美元首付款（折合人民 币约 67.13 亿元），以及最高达 5.5 亿美元（折合人民币约 38.87 亿元）的临床、 注册和销售里程碑付款收购 Arthrosi 100%股权。上述交易完成后，公司将不再 持有 Arthrosi 股权。具体内容参见公司 2025 年 12 月 16 日和 2026 年 1 月 15 日在巨潮资讯网（http://www.cninfo.com.cn）披露 ...

2月3日，一品红盘中上涨2.00%，截至13:17，报33.61元/股，成交1.24亿元，换手率0.89%，总市值 151.81亿元。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：高血压防治、多胎概念、 医保、创新药、肝炎概念等。 截至1月31日，一品红股东户数3.05万，较上期增加14.93%；人均流通股13705股，较上期减少12.99%。 2025年1月-9月，一品红实现营业收入8.14亿元，同比减少34.35%；归母净利润-1.36亿元，同比增长 44.80%。 一品红今年以来股价涨0.18%，近5个交易日跌5.03%，近20日跌6.35%，近60日跌31.24%。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 分红方面，一品红A股上市后累计派现3.35亿元。近三年，累计派现1.51亿元。 资金流向方面，主力资金净 ...

证券日报网讯 2月2日，一品红发布公告称，截至2026年1月31日，公司通过回购专用证券账户以集中竞 价交易方式累计回购公司股份数量为277.34万股，占公司总股本的0.61%，最高成交价为37.85元/股，最 低成交价为32.15元/股，成交均价为34.95元/股，已使用资金总额为9，692.67万元（不含手续费）。 （文章来源：证券日报） ...

（记者 张明双） 每经头条（nbdtoutiao）——曾卖劳斯莱斯、保时捷等豪车，汽车销售巨头宝利德如今破产清算：杭州 总部已人去楼空，义乌子公司贴上了封条 每经AI快讯，一品红2月2日晚间发布公告称，截至2026年1月31日，公司通过回购专用证券账户以集中 竞价交易方式累计回购公司股份数量为277.34万股，占公司总股本的0.61%，最高成交价为37.85元/股， 最低成交价为32.15元/股，成交均价为34.95元/股，已使用资金总额为9692.67万元。 ...